By Fineline Cube 
NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed a Series A financing round, raising “tens of millions” of US dollars. The funding was led by Shanghai Healthcare Capital, with participation from existing investor Lapam Capital and Cherami Investment. The proceeds will be directed toward the clinical development of its core programs focused on central nervous system (CNS) disorders.
Company and Product Pipeline
NeuShen Therapeutics is dedicated to innovative drug research and development for CNS disorders. The company employs dual research platforms, including AAV-based gene therapy and small molecule discovery. Its product pipeline includes NS-041, a selective KCNQ2/3 channel agonist that has completed Phase I clinical trials for indications such as epilepsy, emotional disorders, and pain. Additionally, NS-136, an M4 muscarinic acetylcholine receptor positive allosteric modulator, targets agitation symptoms associated with dementia, including schizophrenia and Alzheimer’s disease. The pipeline also features multiple projects addressing refractory depression, Alzheimer’s disease, and Parkinson’s disease.-Fineline Info & Tech